There may soon be a new upstart entering the ED market - in a few days, the FDA will be reviewing Avanafil, the quick-acting PDE5 inhibitor. The drug has already been approved in Korea, and has gone through Phase III testing in the US. Chances are, it will get approved in the US.
So, will another ED drug have an impact on the market? Probably not much, given that they all do pretty much the same thing. Avanafil's benefit is that it gets things going a bit faster than Viagra or other drugs and therefore might appeal to different users:
"Men who have a pattern of sexual activity that's predictable -- every Saturday night, or something like that, don't need this." Dr. Ira Sharlip a urologist at UC San Francisco and expert in the field of sexual medicine, sees the drug appealing to those who have more casual or sporadic encounters "If you see that things are heading in that direction, you pop a pill and are ready in 15 minutes, if correct."
On the other hand, Avanafil clears the system quicker, so while it may cut down the wait time for the fun to start , it may be over sooner too.
One thing Avanafil has in its favor is that the side effects seem to be milder, especially the more serious cardiac symptoms. The headaches and stuffy nose just seem to come with the territory, but most users tolerate them.
Sharlip had an interesting take on some of Viagra's other supposed side-effects. "Despite what the FDA says, I have never seen priapism from any PDE5 inhibitor drug. Priapism is just not a clinical problem. Blue vision with Viagra is uncommon and at worst annoying. Most men who get the blue vision with Viagra don't care about it," he said.
Huh. I'd think that would be a little disturbing, but who knows - maybe some people like looking at the world through Viagra tinted"glasses.
